公开(公告)号：US10086085B2

公开(公告)日：2018-10-02

申请号：US14605697

申请日：2015-01-26

Applicant: Pfizer Inc.

Inventor： Andreas Maderna ,  Matthew David Doroski ,  Zecheng Chen ,  Hud Lawrence Risley ,  Jeffrey Michael Casavant ,  Christopher John O'Donnell ,  Alexander M. Porte ,  Chakrapani Subramanyam

IPC: C07D487/04 ,  C07D487/06 ,  C07D209/30 ,  A61K31/404 ,  A61K31/407 ,  A61K47/48 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/675 ,  A61K31/7056 ,  A61K38/05 ,  A61K38/06 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07F9/6561 ,  C07H17/02 ,  C07K5/06 ,  C07K5/08 ,  C07K9/00 ,  A61K47/68

Abstract: Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.

公开(公告)号：US20240181028A1

公开(公告)日：2024-06-06

申请号：US18513738

申请日：2023-11-20

Applicant: Pfizer Inc.

Inventor： Catherine Alex ,  Annaliesa Sybil Anderson ,  Bishwa Raj Bhetuwal ,  Zecheng Chen ,  Kaushik Dutta ,  Caitlyn Gallagher ,  Jianxin Gu ,  Isis Kanevsky ,  Jin-Hwan Kim ,  Justin Keith Moran ,  Suddham Singh ,  Naveen Surendran ,  Abhishek Ravindra Vartak ,  YuYing Yang

IPC: A61K39/09 ,  A61K47/64

CPC classification number: A61K39/092 ,  A61K47/646

Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in Prevnar, Synflorix and/or Prevnar 13. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

公开(公告)号：US11365263B2

公开(公告)日：2022-06-21

申请号：US17091097

申请日：2020-11-06

Applicant: PFIZER INC.

Inventor： Andreas Maderna ,  Chakrapani Subramanyam ,  Lawrence N. Tumey ,  Zecheng Chen ,  Jeffrey M. Casavant

IPC: C07K16/32 ,  C07D519/00 ,  C07F9/6561 ,  C07K5/062 ,  C07K5/09 ,  C07B59/00 ,  C07K16/28 ,  C07D495/04 ,  A61K47/68 ,  A61K47/65

Abstract: The present invention is directed to novel bifunctional CTI-CTI and CBI-CTI dimers of the formula: F1-L1-T-L2-F2 where F1, L1, T, L2 and F2 are as defined herein, useful for the treatment for proliferative diseases, where the inventive dimers can function as stand-alone drugs, payloads in antibody-drug-conjugates (ADCs), and linker-payload compounds useful in connection with the production or administration of such ADCs; and to compositions including the aforementioned dimers, linker-payloads and ADCs, and methods for using these dimers, linker-payloads and ADCs, to treat pathological conditions including cancer.

公开(公告)号：US08575159B2

公开(公告)日：2013-11-05

申请号：US13718928

申请日：2012-12-18

Applicant: Pfizer Inc.

Inventor： Aranapakam Mudumbai Venkatesan ,  Zecheng Chen ,  Christoph Martin Dehnhardt ,  Osvaldo Dos Santos ,  Efren Guillermo Delos Santos ,  Arie Zask ,  Jeroen Cunera Verheijen ,  Joshua Aaron Kaplan ,  David James Richard ,  Semiramis Ayral-Kaloustian ,  Tarek Suhayl Mansour ,  Ariamala Gopalsamy ,  Kevin Joseph Curran ,  Mengxiao Shi

IPC: A61K31/535 ,  C07D413/14

CPC classification number: C07D401/12 ,  A61K31/5377 ,  A61K45/06 ,  C07D251/18 ,  C07D401/04 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/12 ,  C07D413/04 ,  C07D413/14 ,  C07D451/06 ,  C07D453/02 ,  C07D491/113 ,  C07D498/08

Abstract: Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.

公开(公告)号：US10391182B2

公开(公告)日：2019-08-27

申请号：US16053344

申请日：2018-08-02

Applicant: PFIZER INC.

Inventor： Andreas Maderna ,  Matthew David Doroski ,  Zecheng Chen ,  Hud Lawrence Risley ,  Jeffrey Michael Casavant ,  Christopher John O'Donnell ,  Alexander M. Porte ,  Chakrapani Subramanyam

IPC: C07D487/04 ,  C07D487/06 ,  A61K47/68 ,  A61K31/404 ,  A61K31/407 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/675 ,  A61K31/7056 ,  A61K38/05 ,  A61K38/06 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07F9/6561 ,  C07H17/02 ,  C07K5/06 ,  C07K5/08 ,  C07K9/00

Abstract: Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.